Show Summary Details
Page of

Innovative drug development for headache disorders: glutamate 

Innovative drug development for headache disorders: glutamate
Innovative drug development for headache disorders: glutamate

Kirk W. Johnson

, Eric S. Nisenbaum

, Michael P. Johnson

, Donna K. Dieckman

, Amy Clemens-Smith

, Edward R. Siuda

, Colin P. Dell

, Veronique Dehlinger

, Kevin J. Hudziak

, Sandra A. Filla

, Paul L. Ornstein

, Nabih M. Ramadan

, and David Bleakman

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 January 2022

Chapter 22 discusses the emergence of selective pharmacological tools that allow activation or blockade of glutamate receptors have provided further insight into the role of glutamate in migraine, and potential therapies.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.